The V Foundation is now accepting Letters of Intent for its 2027 Adult Translational Cancer Research Award. Because only one nomination may be submitted from each institution, UMGCCC will conduct an internal review process to select its institutional nominee.
If you would like to be considered for this opportunity, please submit a one-page abstract and NIH biosketch, to Sarah Laye and Danielle Stegman no later than Friday, November 13, 2026.
________________________________________________________________________________________
Purpose of Award:
This Request for Applications (RFA) is specifically for the adult Translational grant mechanism. Each invited institution may submit one nomination.
Translational Grant Objectives:
Translational research is a critical part of the research continuum, advancing basic laboratory discoveries toward clinical application to improve human health. This grant is restricted to adult cancer research in the preclinical or translational space, with a focus on benchto-bedside strategies. Research on ANY adult cancer type is eligible. Applicants may propose cancer research projects that:
- Move a novel strategy from the laboratory into a human clinical trial, or
- Use specimens from a clinical trial to test hypotheses, develop biomarkers, or establish mechanisms.
The research must apply in a direct way to human beings within 3 years of the grant’s completion. If biomarker research is undertaken, a validation set or independent clinical trial is essential. Proposals must include a plan for biomarker validation, if applicable. The endpoint of the project should be the planning or initiation of a new clinical trial or conducting an investigator-initiated trial with laboratory correlates that test hypotheses. Research areas not included in this scope are epidemiology, behavioral science, and health services research.